At Remi Therapeutics, we believe autism is not a simple behavioral problem. It’s a biological condition—driven by neuroinflammation, oxidative stress, and dysfunctional neural signaling. And biology can be treated.
Our therapies are designed to restore what’s possible: clearer thinking, calmer emotions, stronger focus, and greater independence. Our assets address the core drivers of behavioral dysregulation: neurotransmitter imbalance, neuroinflammation and redox-driven cellular stress. It’s built for the real-world struggles of people and families managing a life touched by autism
Company Details
- Employees
- 3
- Founded
- 2024
- Address
- The Core Drivers Of Behavioral Dysregulation: Neurotransmitter Imbalance
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.remitherapeutics.com
- Keywords
- Milwaukee.
- Competitors
- Fund Governance Analytics, LLC, Pyxis Laboratories, Bivium Biosciences, Luminary Evaluation, Shield Therapeutics plc, The Monte Foundation, Budget Mentor, Inc., ConfluenceStat LLC, Oscillo Biosciences, Professional Analysis and Consulting, Inc. - Engineering, Forensic, and Scientific Expertise.
Remi Therapeutics Questions
Remi Therapeutics's website is http://www.remitherapeutics.com
Remi Therapeutics's LinkedIn profile is https://www.linkedin.com/company/remitherapeutics
Remi Therapeutics has
3 employees.
View email and phone details for 3
employees at Remi Therapeutics.
Remi Therapeutics's industry is
Biotechnology Research
Remi Therapeutics's top competitors are
Fund Governance Analytics, Llc,
Pyxis Laboratories,
Bivium Biosciences,
Luminary Evaluation,
Shield Therapeutics Plc,
The Monte Foundation,
Budget Mentor, Inc.,
Confluencestat Llc,
Oscillo Biosciences,
Professional Analysis And Consulting, Inc. - Engineering, Forensic, And Scientific Expertise.
Remi Therapeutics's categories are Biotechnology Research
Remi Therapeutics's founding year is 2024
